Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 148,118 shares, a decline of 38.3% from the July 30th total of 240,225 shares. Approximately 0.0% of the company's shares are sold short. Based on an average daily trading volume, of 159,888 shares, the short-interest ratio is currently 0.9 days.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on DSNKY shares. Zacks Research downgraded Daiichi Sankyo from a "hold" rating to a "strong sell" rating in a research report on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Reduce".
Check Out Our Latest Report on DSNKY
Daiichi Sankyo Price Performance
Shares of OTCMKTS:DSNKY opened at $18.38 on Monday. The business has a fifty day moving average price of $17.04 and a 200-day moving average price of $17.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The company has a market capitalization of $34.24 billion, a PE ratio of 21.37, a PEG ratio of 2.52 and a beta of -0.18. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $27.50.
Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. The firm had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities analysts expect that Daiichi Sankyo will post 0.97 EPS for the current fiscal year.
About Daiichi Sankyo
(
Get Free Report)
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Daiichi Sankyo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.
While Daiichi Sankyo currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
